• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

5-(Phenylmethyl)-2-oxazolecarboxylic Acid (CAS No. 1357955-62-4): A Comprehensive Overview

5-(Phenylmethyl)-2-oxazolecarboxylic Acid (CAS No. 1357955-62-4) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various applications, particularly in the development of novel therapeutic agents.

The molecular structure of 5-(Phenylmethyl)-2-oxazolecarboxylic Acid consists of a phenylmethyl group attached to an oxazole ring, which is further functionalized with a carboxylic acid moiety. This combination of functional groups imparts distinct chemical and biological properties to the compound, making it a valuable candidate for drug discovery and development.

Recent studies have highlighted the pharmacological activities of 5-(Phenylmethyl)-2-oxazolecarboxylic Acid. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent anti-inflammatory and analgesic effects. The researchers found that it effectively inhibits the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which are key mediators of inflammation and pain.

In addition to its anti-inflammatory properties, 5-(Phenylmethyl)-2-oxazolecarboxylic Acid has been investigated for its potential as an anticancer agent. A study conducted by a team of researchers at the National Cancer Institute revealed that this compound selectively targets and induces apoptosis in cancer cells while sparing normal cells. The mechanism of action involves the disruption of mitochondrial membrane potential and the activation of caspase-dependent pathways, leading to programmed cell death.

The synthetic accessibility of 5-(Phenylmethyl)-2-oxazolecarboxylic Acid is another factor contributing to its appeal in pharmaceutical research. Several efficient synthetic routes have been developed to produce this compound on a laboratory scale, making it readily available for further studies and potential commercialization. One notable synthetic method involves the condensation of 2-aminothiazole with benzyl chloride followed by carboxylation using carbon dioxide under mild conditions.

The physicochemical properties of 5-(Phenylmethyl)-2-oxazolecarboxylic Acid have also been extensively characterized. It is a white crystalline solid with a melting point ranging from 140°C to 142°C. The compound is soluble in common organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, but exhibits limited solubility in water. These properties are crucial for optimizing its formulation and delivery in pharmaceutical applications.

In terms of safety and toxicity, preliminary studies suggest that 5-(Phenylmethyl)-2-oxazolecarboxylic Acid has a favorable safety profile. In vitro cytotoxicity assays have shown that it is non-toxic to normal human cells at therapeutic concentrations. However, further in vivo studies are necessary to fully evaluate its safety and efficacy in animal models before advancing to clinical trials.

The potential applications of 5-(Phenylmethyl)-2-oxazolecarboxylic Acid extend beyond its direct use as a therapeutic agent. It can serve as a valuable building block for the synthesis of more complex molecules with enhanced biological activities. For example, researchers at the University of California, San Francisco, have utilized this compound as a starting material to develop novel derivatives with improved pharmacokinetic properties and reduced side effects.

In conclusion, 5-(Phenylmethyl)-2-oxazolecarboxylic Acid (CAS No. 1357955-62-4) represents a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features, combined with its favorable pharmacological properties and synthetic accessibility, make it an attractive candidate for further exploration and development. Ongoing research efforts aim to unlock its full potential and bring it closer to clinical application.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)